Donga Pharmaceutical announced on July 24 that its oral care brand "Duobuster" has launched a new product, "Duobuster Oral Balance Probiotic for Oral Health," featuring a dual-layer tablet design.


Donga Pharmaceutical Launches 'Duobuster Oral Balance Probiotic for Oral Health'. Donga Pharmaceutical

Donga Pharmaceutical Launches 'Duobuster Oral Balance Probiotic for Oral Health'. Donga Pharmaceutical

View original image

According to the company, the Duobuster Oral Probiotic uses a dual-layer tablet structure—consisting of a mint layer and a white layer—to prevent probiotics from coming into direct contact with sensitive ingredients. The probiotics and functional sub-ingredients are designed to be separated. This marks the first time a dual-layer design has been introduced among oral probiotics in Korea.


The new product utilizes a patented strain, S.SALIVARIUS G7, which was isolated from the gums of Korean individuals. The company explained that this strain was developed specifically for the Korean oral environment through domestic research. The product improves upon the characteristic dry texture and taste of typical oral probiotics and contains no added sugars. With a tablet diameter of 11.5 mm, it is suitable for consumption by both children and adults, as noted by the company.


The brand’s previous offering, "Duobuster Mint Ball," surpassed cumulative sales of 1 million units within a year of its launch last year. With this new product, Donga Pharmaceutical plans to expand the brand's "dual" concept to its line of oral probiotic products.



A Donga Pharmaceutical representative stated, "This new product is the first in the country to feature a dual-layer tablet design, offering enhanced safety and convenience of intake for oral probiotics." The spokesperson added, "We plan to continue introducing a variety of oral care solutions so that consumers can more easily and effectively maintain oral health in their daily lives."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing